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Nitric oxide (NO) mediated slow inhibitory junction potential and mechanical relaxation
after electrical field stimulation (EFS) is impaired in diabetes mellitus. Externally added NO
donor restore nitrergic function, indicating that this reduction result from diminution of NO
synthesis within the pre-junctional nerve terminals.The present study aimed to investigate
two specific aims that may potentially provide pathophysiological insights into diabetic nitr-
ergic neuropathy. Specifically, alteration in nNOSα contents within jejunal nerve terminals
and a local subcortical transporter myosin Va was tested 16 weeks after induction of dia-
betes by low dose streptozotocin (STZ) in male Wistar rats. The results show that diabetic
rats, in contrast to vehicle treated animals, have: (a) nearly absent myosin Va expression
in nerve terminals of axons innervating smooth muscles and (b) significant decrease of
myosin Va in neuronal soma of myenteric plexus. In contrast, nNOSα staining in diabetic
jejunum neuromuscular strips showed near intact expression in neuronal cell bodies. The
space occupancy of nitrergic nerve fibers was comparable between groups. Normal con-
centration of nNOSα was visualized within a majority of nitrergic terminals in diabetes,
suggesting intact axonal transport of nNOSα to distant nerve terminals. These results
reveal the dissociation between presences of nNOSα in the nerve terminals but deficiency
of its transporter myosin Va in the jejunum of diabetic rats. This significant observation of
reduced motor protein myosin Va within jejunal nerve terminals may potentially explain
impairment of pre-junctional NO synthesis during EFS of diabetic gut neuromuscular strips
despite presence of the nitrergic synthetic enzyme nNOSα.
Keywords: axonal transport, myosin Va, nNOS, diabetes, neuropathy
INTRODUCTION
Slow inhibitory junction potentials (sIJP) are recorded using
impaled electrodes within gastrointestinal smooth muscles in
response to nitric oxide (NO) released from pre-junctional nerve
terminals after electrical field stimulation (EFS). Independent
studies have confirmed impairment of sIJP in muscle samples
obtained from all portions of the gastrointestinal tract of animals
with pharmacologically induced or genetically acquired diabetes
mellitus (1–3). Mechanical studies have confirmed diminution
of EFS-mediated nitrergic relaxations in diabetic enteric tissues
like ileum and mid-colon (3–7). Some of these studies have also
demonstrated restoration of nitrergic mediated responses in dia-
betic tissues with externally added NO donor to the organ bath
(4–6), indicating that the diminution of nitrergic function in dia-
betic gut tissues resulted primarily from reduction or inhibition
of NO synthesis within the pre-junctional nerve terminals.
Controversy exists in the reports regarding the content of neu-
ronal nitric oxide synthase (nNOS) within the enteric nerve termi-
nals in diabetic gut tissues. Limited data showing only a single low
power microscopic field have been used to report reduced number
of nitrergic axons traversing the neuromuscular wall in streptozo-
tocin (STZ) induced diabetes (8). Other studies have reported
reduced dimer/monomer ratio of nNOS (9) or increase in total
nNOS levels in diabetes (9, 10). However, the nNOS blots were
run with extracts obtained from whole gut tissues, thus precluding
specific information about nNOS contents within the nerve ter-
minals per se. Studies have also reported normal nNOS enzymatic
activity of diabetic whole gut extracts assayed in vitro (11). How-
ever, none of these studies provide unequivocal evidence about
nNOS contents within the nerve terminals, the site of inhibitory
enteric neuromuscular nitrergic neurotransmission.
Recently, evidence has been provided that mere presence of
nNOS within nerve terminals is not adequate for pre-junctional
NO synthesis (12–14). The regulation of nNOS within the nerve
varicosities require multiple allosteric interactions, most notably,
its positioning at PDZ-rich active zones that allow interfacing of
water soluble nNOSα with membrane-bound palmitoyl-PSD95
(14, 15). Intriguingly, this binding of nNOSα is not stochastic
and dependent on a Brownian kind of diffusion but rather relies
on specific molecular interactions involving motor proteins like
myosin Va that have the ability to deliver nNOSα to membrane-
binding sites (12). Using a mouse model of myosin Va mutation,
the dilute DBA/2J mice, it was shown that in vitro NO synthe-
sis of enteric synaptosomes and NO-mediated sIJP and l-NAME
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sensitive mechanical relaxations were impaired in gastric tissues
of dilute mice (12, 14).
The purpose of the present study was to investigate two specific
aims that may potentially provide pathophysiological insights into
diabetic enteric nitrergic neuropathy: (a) is there any alteration in
nNOS contents within enteric nerve terminals in diabetes (b) is
there any alteration in myosin Va contents within enteric nerve
terminals in diabetes. The first question was pursued to obtain
unambiguous evidence about the state of nitrergic nerve termi-
nals in diabetes at a fixed time point after diabetes induction.
Based on preliminary evidence that local intravaricosity transport
of nNOSα by myosin Va motor protein is important for efficient
NO synthesis during neurotransmission (12, 13), we hypothesized
that deficiency of myosin Va may contribute to impaired nitrergic
neurotransmission in diabetes.
MATERIALS AND METHODS
INDUCTION OF DIABETES MELLITUS
All experimental procedures were conducted with approval from
IACUC Committee of VA Boston HealthCare System (VABHS)
and Committee of Ethics in Animal Experimentation from the
Universidade Estadual de Maringa’. Male Wistar rats (Rattus
norvegicus) from the Central Biotery of Universidade Estadual
de Maringa’ were utilized for the present investigation. Ninety-
day-old rats were maintained in separate cages for 4 months
prior to experimentation. After a 14-h fast, STZ (35 mg/kg body
weight; Sigma, St. Louis, MO, USA) dissolved in freshly prepared
10 mM citrate buffer (pH 4.5) was intravenously injected. Ani-
mals with persistent plasma glucose >250 mg% were used for
the study as a model of diabetes mellitus. Normoglycemic vehicle
treated animals were used as controls. Jejunum were obtained after
4 months of diabetes induction. Details of tissue procurement and
euthanasia procedures have been described earlier (16).
STAINING OF JEJUNAL WHOLE MOUNTS FOR MYOSIN Va AND nNOSα
Details of tissue fixation and staining were performed as per
protocols described earlier (16). Jejunum was used as represen-
tative of gut neuromuscular strip. A polyclonal antibody raised
against chicken brain myosin Va (17) and extensively charac-
terized previously was used for myosin Va immunostaining (1
in 750 primary, prepared at University of São Paulo, Ribeirão
Preto-campus). Tissue reaction was performed by incubating with
hydrogen peroxide and diaminobenzidine (DAB). Omission of
the primary antibody did not show any reaction product after
labeling. nNOSα immunostaining was performed with a com-
mercial antibody developed against epitope N2–300 (H-299, 1 in
500, Santa Cruz Biotechnology) with appropriate negative control.
Avidin–biotin histochemistry and Alexa Fluor fluorescent images
were separately obtained to visualize nNOSα immunostaining.
Uniform staining protocols were used.
LIGHT MICROSCOPIC IMAGING OF WHOLE MOUNTS AND ACQUISITION
OF IMAGES
Digitized images were obtained with Zeiss Axioskop Plus light
microscope at 200-fold magnification and stored for offline
analyses. Same scaled images were used for comparative analy-
ses, though digitally zoomed images may have been shown as
representative figures for better depiction of the projected features.
PSEUDOCOLORING OF IMAGES FOR CREATING CONTRAST AND
BETTER VISUALIZATION OF NEUROMUSCULAR STRUCTURES
Some image profiles were pseudocolored to create better contrast
for visualization of neuromuscular apparatus. Images were opened
in ImageJ (NIH freeware)1 and converted to 16- or 32-bits prior
to choosing a pseudocolor (sepia, magenta hot, blue orange icb,
and glasbey) from the lookup table (LUT) for creating efficient
contrast.
QUANTITATION OF SPACE OCCUPANCY OF NITRERGIC VARICOSITIES
Space occupancy of nitrergic varicosities was obtained using a
simple derivative of graph theory. Graph theory relies on connec-
tivity patterns based on number of vertices and edges and maybe
expressed as: G= (V, E) (18, 19). The nerve varicosities may be
inferred as the vertices (V ) and the axonal processes (primary, as
well as branches) to be edges (E). Based on the argument that
cable length and sites of neurotransmission (junctions or varicosi-
ties) are critical for determining efficiency of neurotransmission
(20), obtaining quantitative information on spatial densities will
be a more reliable marker of neurites’ arborization rather than
random visualization of a snapshot of a whole mount micro-
scopic field. Quantizing the pixel intensities of varicosities and the
processes provide a semiquantitative approach toward estimat-
ing whether any changes occurred in the spatial density of nerve
terminals after diabetes induction. In order to obtain pixel inten-
sities of axonal processes, repeated thresholding was performed in
ImageJ to remove background intensity. The auto-threshold func-
tion (Huang, intermodes, Li, maximum entropy, and isodata) in
ImageJ was used for these analyses. RGB images were converted to
8 or 16-bit prior to thresholding.
3D SURFACE MODELING TO VISUALIZE MYOSIN Va MUSCULOMOTOR
TERMINALS
The plugin 3D interactive surface plot in ImageJ was used to visual-
ize the stained varicosities and myenteric plexus. Unaltered images
were used for these quantitative analyses. The spike height and
color hue are representative of immunoexpression intensity. Same
parameters of grid size, smoothing, perspective, and lighting were
used for all whole mounts analyzed.
ESTIMATION OF nNOSα CONTENTS WITHIN NITRERGIC VARICOSITIES
Varicosities were carefully outlined with freehand selection tool
in ImageJ and area and integrated densities estimated for nNOSα
concentrations within varicosities and intensities normalized to
area. Axonal processes were carefully traced from the cell body
toward the ramification on the muscular wall and followed till the
process ended or faded in a different plane. This information was
also used to map a static kymograph that provided insights into
nNOSα axonal transport in vehicle treated and STZ-induced dia-
betes. Linear distances between varicosities were measured. Raw
images were used for intensity analyses.
NEURONAL PROCESS TRACING
Free hand tools were used to trace nitrergic neurons on planar
unscaled whole mounts in MS Paint. The trace was independently
1http://imagej.nih.gov/ij
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FIGURE 1 | Low power micrographs from jejunal whole mounts of vehicle treated (left) and streptozotocin induced diabetic rats (right). Note the
obvious differences in DAB staining intensity of myosin Va between the two panels. Scale bar, 25µm.
visually verified in NeuronJ2 (data not shown) (21). Random selec-
tions of neurons were made from independent whole mounts
obtained from different rats.
STATISTICAL ANALYSES
Quantitative data was expressed as mean± SEM. Two-tailed t test
was used to compare difference between means of the parametric
datasets.
RESULTS
MYOSIN Va IMMUNOREACTIVITY IS SCANT OR NEARLY ABSENT IN
THE NEURO-SMOOTH MUSCLE NERVE TERMINALS OF JEJUNUM
In contrast to the vehicle treated rats, induction of diabetes by
STZ resulted in nearly complete loss of myosin Va within the
nerve terminals of the neuronal processes ramifying on the mus-
cularis externa (Figure 1). Whole mounts of jejunum stained with
myosin Va specific antibody failed to show the brown reaction
product of DAB staining that was visualized in the enteric tis-
sues of normal rats (Figure 1). The absence or paucity of myosin
Va staining overlying the muscularis externa was apparent during
light microscopic imaging.
MYOSIN Va IMMUNOREACTIVITY IS VARIABLY DECREASED OR NEARLY
ABSENT IN MANY NEURONAL CELL BODIES OF MYENTERIC PLEXUS OF
JEJUNUM
In wild type condition, myosin Va immunoreactivity was strongly
present in the cell bodies of all neurons present within the myen-
teric plexus. The brown reaction product was well visualized and
uniformly distributed across the whole cytosol of the neuronal
soma. Myosin Va immunoreactivity was also well visualized in the
axon initial segment (AIS) of the ganglionic neurons and extended
into the processes that link different cells within the ganglion, as
well as axonal extensions into the muscularis (Figure 2). There was
diffuse staining for some length of the initial parts of the axonal
extensions, but thereafter, myosin Va immunoreactivity was seen
as regular punctate appearance, indicating probable concentration
2http://www.imagescience.org/meijering/software/neuronj/
of myosin Va in the nerve varicosities of the neuro-smooth muscle
neuromuscular junctions.
In contrast, myosin Va immunoreactivity was severely dimin-
ished in most neuronal cell bodies in diabetic jejunal whole
mounts (Figure 2). In the neuronal cell bodies that demonstrated
reduced staining,myosinVa immunoreactivity did not extend even
into the AIS (Figure 2). Significantly, no myosin Va immunoreac-
tivity was seen even in the initial portions of the axonal extensions
in diabetic jejunum. Myosin Va immunoreactivity was only scant-
ily and rarely present in the nerve varicosities overlying the mus-
cularis in diabetic tissues (Figure 3). Light microscopic imaging
reveals the variance of the myosin Va staining and distribution
within the ganglion neurons and its arborizations in diabetic
tissues (Figure 4). Molecular techniques like western blotting
of whole tissue protein extracts would fall short in identifying
this significant observation. Because of only sporadic presence of
spotty myosin Va-IR within nerve varicosities of diabetic tissues
(Figure 3), quantitative myosin Va concentrations within nerve
terminals of the neuromuscular junctions were not obtained.
UNLIKE MYOSIN Va, nNOSα IMMUNOREACTIVITY IS NORMAL IN THE
NEURO-SMOOTH MUSCLE NERVE TERMINALS OF JEJUNUM
nNOSα immunoreactivity within the nerve terminals in vehicle
treated and STZ-induced diabetic jejunal tissues was quantita-
tively examined. nNOSαwas present within the nerve terminals of
both vehicle treated and STZ-treated rats (left panels of Figures 5
and 6). Also note that the nerve terminals and nitrergic axons
form loop like structures, reminiscent of Kirchoff-type circuits.
This distribution may serve to propagate inhibitory nerve signals
simultaneously over a segment of muscle, though no electro-
physiological evidence or imaging evidence of simultaneous NO
production over the loop with a single electrical stimulus has ever
been obtained.
nNOSα IMMUNOREACTIVITY IS NORMAL OR VARIABLY DECREASED IN
THE NEURONAL CELL BODIES OF MYENTERIC PLEXUS OF JEJUNUM
The variance of nNOSα expression is demonstrated in the right
panels of Figures 5 and 6 (vehicle and STZ treatment, respectively).
The cellular expression of nNOSα is comparable between vehicle
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FIGURE 2 | Myosin Va immunoreactivity extending from the cell body
to the processes of Dogiel type 2 neurons emanating from myenteric
plexus. In vehicle treated group (left panel), myosin Va is present in the
initial segment, as well as axonal processes extending to the muscle
layers. Myosin Va is also present in the interneuronal processes within the
ganglion. In contrast, note that in the diabetic rats, despite the presence of
secondary plexus linking the ganglia and tertiary extensions of nerve
processes into the muscle layers, the brown DAB reaction product
representative of myosin Va presences is scant or nearly absent in these
processes. Scale bar, 25µm.
FIGURE 3 | 3D surface plot of DAB staining intensity of myosin Va in WT
and diabetic jejunum. Note that in vehicle treated rats (upper panels),
staining spikes present in the muscle segments interposed between the
ganglia and plexuses have dense distribution of myosin Va spikes in the nerve
terminals, while these spikes within the muscularis are almost absent in
diabetic tissues (lower panels). These nerve terminals are the sites of
neuro-smooth muscle neurotransmission. Note the lighter hue of the staining
spikes within the neuronal cell bodies, representative of reduction in myosin
Va genomic expression within the neuronal soma in diabetic tissues in
comparison to vehicle treated rats. Scale bar, 15µm.
treated normal (Figure 5) and STZ-treated diabetic jejunum
(Figure 6). While most of the cells are uniformly stained in the
wild type tissues with comparable pixels of expression, the fourth
segment in the right panel (Figure 5) shows cell bodies with
comparatively low expression of staining. The reason to demon-
strate this variance is to stress that mere comparative expres-
sion from whole tissue extracts by protein blotting techniques
is not optimal to obtain evidence regarding the neuropathology
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FIGURE 4 | Details of myosin Va staining of ganglionic neurons and
their processes in diabetic jejunum. Note the heterogeneity of
appearance of myosin Va in the cell bodies of the neurons in the myenteric
plexus. In the left panel, note the moderate staining in the cell bodies of
many neurons. Also note that the secondary plexus running to the left of
the image has some brown DAB staining. Some of the neuromuscular
varicosities have faint brown staining. In the middle panel, note the enlarged
neuronal soma with unhealthy appearing nucleus, possibly indicating a
degenerating neuronal cell body. The increase in size may be related to the
cellular accumulation of myosin Va, possibly resulting from stasis of myosin
Va axonal transport. Also note the absence of brown staining in all of the
neuronal processes ramifying through the muscular wall. The right panel
recapitulates information represented in the middle panel and in addition,
shows a full range of neuronal cytopathology. Note that in the upper pole,
two neurons do not have any cytoplasmic staining and the lower neuron is
possible degenerative, as evidenced by unusual nuclear appearance. Note
very scant or nearly absent staining in the interneuronal processes,
secondary plexi as well as tertiary neuromuscular nerve varicosities. Also
note that some cells (top right, also one cell body in the right on left panel)
show intense dark brown staining. This heterogeneous appearance may
result from enhanced myosin Va transcription but may have also resulted
from myosin Va aggresome formation. Scale bar, 25µm.
of nNOSα expression. Some of the neuronal cell bodies demon-
strate lower levels of expression of nNOSα (Figure 6). However,
nNOSα was present in the neuronal processes arising from these
cell bodies. Most whole mounts actually demonstrated normal
levels of expression of nNOSα in the diabetic tissues. Occasion-
ally, apoptotic neuronal cells with high nucleocytoplasmic ratios
and skeletonized outlines were observed (Figure 6, lower segment
of the right panel).
NITRERGIC NEURONAL PROCESSES ON MUSCULARIS EXTERNA
ARBORIZE NORMALLY AND SHOW NO RETRACTION IN DIABETIC
JEJUNUM
Observations of the whole mounts show wide variance in the dis-
tribution patterns of the processes emanating from the ganglionic
neuronal cell bodies and extending to the muscularis externa.
Representative tracings indicating this variance is demonstrated
in both vehicle treated and diabetic tissues in Figure 7. Several
nitrergic neuronal processes were traced and compared between
vehicle treated and diabetic tissues. The neuronal arborizations
were extensive and cable length comparable between sham treated
and diabetic tissues, indicating no retraction of neuronal processes
of nitrergic neurons that ramify on the muscularis in diabetes
(Figure 7, lower panel). Semiquantitative parameters like the
distance of the farthest point on the axonal process from the
centroid of the neuronal cell body were used to compare neural
arborization. These data were comparable between vehicle and
STZ treatment (data not shown).
nNOSα IS NORMALLY DISTRIBUTED IN THE CELL BODIES OF
MYENTERIC PLEXUS AND EXTENDS INTO THE DENDRITES OF DOGIEL
TYPE 1 NEURONS AND INTERNEURONAL PROCESSES WITHIN
GANGLIA IN DIABETES
nNOSα is present not only in the nerve terminals in diabetes, but
also normally distributed within the cell bodies as well as the den-
drites of Dogiel type 1 neurons. Images were converted to 16-bits
and pseudocolor coded prior to thresholding for optimal visual-
ization of the neuronal cell body and processes. The distribution
of nNOSα in wild type and diabetes in the proximal processes were
comparable (Figure 8). Interneuronal processes between smooth
Dogiel type 2 neurons and axonal extensions into the muscle con-
tained comparable levels of nNOSα in vehicle treated and diabetic
tissues. These qualitative observations indicate that at the time
period examined, nNOSα axonal and dendritic transport is not
impeded despite diabetic condition of the rats. Again, it may be
appreciated that the genomic expression of nNOSα is variable
and may be slightly diminished in some ganglionic neurons. The
intact axonal transport of nNOSα in diabetes is sharply contrasted
against the nearly absent axonal transport of myosin Va in diabetes
at the specific time point examined.
SPACE OCCUPANCY OF NITRERGIC VARICOSITIES ARE COMPARABLE
BETWEEN VEHICLE TREATED AND STZ-INDUCED DIABETIC JEJUNUM
Because of the variance in the distribution patterns of nitrergic
nerve processes within the muscular wall, examination of a single
field of whole mount may not be accurately reflective of axonal
arborization. In order to obtain quantitative evidence of intact-
ness of arborization pattern of nitrergic axons and varicosities,
we incorporated a simple application of graph theory. Essentially,
we argued that a unit of muscle segment delimited on the sides
by ganglion and the primary and secondary plexus constitutes a
unit of muscle bed that is supplied by axonal processes extend-
ing into this region from the adjacent plexi and cell bodies. One
short coming of this approach is that only a planar layer was
examined, while it is possible that the ramification of the nerve
fibers may be deep to the visualized tissue plane. Considering
obtaining a semiquantitative estimate, only planar images were
considered, ignoring the stereological aspect. In comparison to
previous reports, which have shown a single section to comment
on nitrergic nerve process distribution (8), we estimated the total
intensity of the axonal extensions and normalized to the mus-
cular area of distribution. The total intensity was obtained by
numerous iterations of thresholding (Figure 9B), the averaging
technique contributing to closely accurate estimates of pixel inte-
grated densities. In this way, we computed the space occupancy of
nitrergic processes. Because the intervaricose segments are much
less stained than the varicosity regions, so it is logical to extrapolate
this calculation to be an estimate of space occupancy of nitrergic
varicosities. Though some diabetic sections showed a diminu-
tion in extension of nitrergic processes across muscle bed (lowest
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FIGURE 5 | Normal arborization of nitrergic neuronal processes on muscularis in both vehicle treated and diabetes. (A) shows variance in distribution of
the nitrergic processes. (B) shows two traced neurons in each group. Note the complex ramifications patterns. Blue indicates cell body and interganglionic
neuronal connections. Orange color indicates the neuronal processes extending onto the muscularis. Note that varicosities were not traced. Scale bar, 25µm.
FIGURE 6 | nNOSα expression in vehicle treated jejunum. Note the variance of nNOS expression in the neuronal cell bodies in the segments of the right
panels. Scale bar representative of each side, 25µm.
count 153 AU/µm2), cumulative analyses show comparable lev-
els of the space occupancy of nitrergic varicosities (215.25± 0.74
vs. 209.84± 0.82 AU/µm2, p= 0.42, two-tailed t test) (Figures 9A
and 9C).
nNOSα CONCENTRATIONS ARE COMPARABLE BETWEEN VEHICLE
TREATED AND DIABETIC MUSCULOMOTOR NERVE TERMINALS
The preceding analyses suggest that while myosin Va expression
is nearly absent in the motor nerve terminals and significantly
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FIGURE 7 | nNOSα expression in STZ-treated diabetic jejunum. Note the
variance of nNOS expression in the neuronal cell bodies in the segments of
the right panels. Note reduction of nNOSα expression in some cell bodies.
However, the neuronal processes emanating from these cell bodies show
nNOSα expression. Note that the lowest panel shows some degenerating
neuronal cell bodies. Scale bar representative of each side, 25µm.
FIGURE 8 | Normal staining of nNOS within dendritic processes of
Dogiel type 1 neurons and interganglionic neuronal processes in
both vehicle treated and STZ-induced diabetic jejunum. The lower
panels show a digitally zoomed image showing that nNOS extends into
the proximal processes of the nitrergic neurons in both wild type and
diabetic jejunal tissues. Renyi entropy type thresholding of pseudocolored
images were used to observe the neuronal branch pattern morphology.
Scale bar, 25µm.
reduced or absent in the pan-neuronal soma of the myenteric
plexus from which the processes arise, nNOSα-positive nerve
fibers appear normal in diabetic jejunum. Fluorescent images of
nNOSα were used to examine specific nNOSα expression within
the nerve terminals (Figure 10A). The images were thresholded to
define the shape of individual varicosities and ease in estimation
of the area of the varicosity (Figure 10B). Fluorescence intensi-
ties of nNOS expression were normalized to the areas and these
values were comparable between vehicle treated and STZ-induced
diabetic jejunum (18.9± 0.24 vs. 17.32± 0.15 AU/µm2, p= 0.8,
two-tailed t test). The intervaricose distances between nitrergic
varicosities were comparable between vehicle treated and STZ-
induced diabetes (3.22± 0.27 vs. 3.08± 0.18µm) (Figure 10C).
STATIC KYMOGRAPH SHOWS INTACT nNOSα AXONAL TRANSPORT IN
DIABETIC JEJUNUM
Static kymograph of nNOSα axonal transport was computed
(Figure 10C). Nine randomly chosen nitrergic neurons from dif-
ferent rats with traceable and distinctly appearing varicosities in
each group were used to obtain quantitative estimate of nNOSα
axonal transport. The kymograph shows that despite some reduc-
tion of nNOSα expression in few of the nerve terminals, nNOSα
www.frontiersin.org June 2014 | Volume 1 | Article 17 | 7
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FIGURE 9 | Comparable levels of ramifications of nitrergic axonal
processes and varicosities on the muscularis of vehicle treated and
diabetic jejunum. In (A), the 16-bit images were pseudocolored sepia to
focus on expression of the nitrergic varicosities and ignoring appearance of
background during visualization. (B) Shows repetitive iterations of
thresholding performed with NIH ImageJ. Cumulative thresholding helped
subtract background and obtain accurate estimates of pixel intensities of
nitrergic processes. (C) Shows comparative levels of space occupancy of
nitrergic varicosities in wild type and diabetes, suggesting that no axonal
retraction has taken place in diabetic tissues. The variance in the distribution
of the axonal processes may be semiquantitatively expressed by this
parameter of space occupancy derived from graph theory. Scale bar, 25µm.
distribution is comparable between wild type and diabetic axonal
processes, and that nNOSα reaches the farthest neuromuscular ter-
minals in diabetic rats. This indicates that the axonal transport of
nNOSα is likely not impeded in diabetes, unlike myosin Va axonal
transport, which is severely impaired.
DISCUSSION
The results of the current study reveal that in contrast to vehicle
treated rats, jejunum obtained 16 weeks after rats were injected
with low dose STZ show: (a) nearly absent myosin Va expression
in nerve terminals of fibers traversing the enteric neuromuscular
bed, (b) variable decrease of myosin Va in cell bodies within the
myenteric plexus, with near absence of myosin Va in several gan-
glionic neurons, and (c) some presence of myosin Va in the AIS of
ganglionic cell bodies that stained for myosin Va, but near com-
plete absence of myosin Va staining even in the initial segments
of the primary plexus. In contrast, nNOSα staining in diabetic
jejunum neuromuscular strips showed: (a) near intact expression
of nNOSα in neuronal cell bodies, with reduction of expression in
few cell bodies, (b) intact presence of nitrergic nerve fibers, with
normal ramification and arborization patterns of nitrergic nerve
fibers, normal density of nitrergic nerve fibers and terminals in
comparison with untreated animals and normal concentration of
nNOSα within a majority of nerve terminals and intact axonal
transport of nNOSα to distant nerve terminals.
This report has examined the distribution of nNOSα quan-
titatively in diabetic enteric nerve terminals. While there was
reduction of nNOSα expression in some cell bodies, as well as
in some nerve terminals, the images, as well as the quantitative
analyses show that there is a wide variance of expression of nNOSα
both in wild type tissues, as well as after STZ treatment. Thus, mere
western blots of whole gut extracts (9, 10) may not be optimal
approach for revealing the dynamic changes in nNOSα expres-
sion. Cumulative analyses, in fact, reveal that there is no statistically
significant reduction of nNOSα expression within the nerve ter-
minals in STZ-treated rat jejunum. Studies have demonstrated
and discussed the progressive nature of diabetic autonomic neu-
rodegenerative changes (3, 22). The results presented in this study
needs to be cautiously interpreted in the background of the single
time point that has been examined.
The findings of the unaltered expression of nNOSα within the
nerve terminals are sharply contrasted with the near absence of
myosin Va within the neuromuscular nerve varicosities. Quanti-
tative density plots revealed only patchy and spotty appearance of
myosin Va-positive nerve terminals after STZ treatment. It may
be noted that there is a wide variance of myosin Va expression in
the cell bodies comprising the ganglia in diabetes. A wide range
of fields have been shown to demonstrate that an entire spec-
trum of changes has occurred in myosin Va expression within the
neuronal soma after diabetes induction. In some cell bodies, the
myosin Va expression appears comparable to those of untreated
animals. However, most neurons show moderate to severe reduc-
tion of expression of myosin Va. Interestingly, even when myosin
Va expression is visualized within the neuronal soma, it is very
difficult to observe any amount of expression of myosin Va within
the processes emanating from the Dogiel type 1 and 2 neurons.
One possibility may be that the primary processes may be in a dif-
ferent plane than the one visualized and imaged. However, close
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FIGURE 10 | Comparative levels of expression of nNOSα in nerve
terminals of both wild type and diabetic tissues (A). Upper panel shows
variance in appearance of nNOSα in vehicle treated and diabetes.
Comparative quantitation demonstrated similar nNOSα levels within
varicosities. (B) Fluorescent images were thresholded to digitally isolate
individual nitrergic varicosities. Varicosity areas were estimated with ImageJ.
nNOSα fluorescent intensities within varicosities were estimated with
unaltered images. (C) nNOSα static kymograph shows normal axonal
transport of nNOSα in diabetic jejunum to the farthest varicosities.
Intervaricose distances were comparable between groups. Scale bar, 25µm.
visualization failed to show myosin Va in the axonal extensions.
There may be two plausible reasons, which may have contributed
to this state: (a) the low synthesis of myosin Va may have produced
inadequate levels of the protein so that no substantial protein was
available for transport to the axon, (b) this observation may also
result from alterations in the protein quality, e.g., glycosylation of
myosin Va may have transformed the protein to an effete nature,
precluding its normal function and transit to the AIS. Though
myosin Va may be normally partially glycosylated, other studies
have shown that excessively glycosylated myosins have reduced
ATPase activity and ability of force generation through actomyosin
formation (23–25). Succinylated wheat germ agglutinin (sWGA)
based assays have shown that nNOS is not glycosylated (26), thus
creating a dilemma of why nNOS function is so severely affected
by the hyperglycemia of diabetes. The results of the current study
provide the first possible hints into the molecular pathophysiology
of how nitrergic dysfunction may occur in diabetic nerve terminals
due to deficits of molecular motors.
The near complete absence of myosin Va within the proxi-
mal portions of neuronal extensions may also have resulted from
defects in spectrin, which may form an unusual barrier at the axon
hillock and prevented protein migration (27). This possibility is
unlikely, since the results suggest that transport of other soluble
proteins like that of nNOSα has not been impeded. Yet another
possibility may be the result of defect of an allosteric partner
for myosin Va that participates in axonal transport of myosin Va.
Some preliminary evidence has been provided that neurofilament
cooperatively participates in axonal transfer of myosin Va (28).
It has been reported that neurofilament levels may be affected
in pre-diabetic condition (29) and may decrease very early in
diabetes (30). Decreases in neurofilaments have been reported
in myenteric neuronal processes in high-fat diet induced dia-
besity (31). Earlier, it has also been demonstrated that despite
the normal presence of neurofilaments in the soma and axons
of myenteric neurons, a RT97 specific phosphorylated neurofil-
ament epitope was deficient in diabetic rat ileum, and this was
reversed when strips were incubated in insulin for 2 h (32). Alter-
ations of neurofilaments may have potentially contributed to the
total stasis of myosin Va within the nerve cell bodies seen in
the current study. Electron micrographic examinations of neu-
ronal processes within stomach tissues obtained from patients
with diabetic gastroparesis have shown derangement of orienta-
tion of neurofilaments (33). Whether such spatial alterations of
neurofilaments contribute to pathophysiology of loss of axonal
transport of myosin Va in diabetic myenteric plexi remains to be
examined.
The current investigation provides insights into axonal trans-
port of nNOSα and some of the early changes seen in diabetic nerve
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cell bodies and processes. Overall analyses show that nNOSα is
present in the farthest varicosity away from the cell body, in com-
parable concentrations to those seen in untreated animals. The
arborization patterns remain unaltered and the numbers of nerve
terminals on each process are comparable between untreated and
diabetic samples, indicating that there is no neurite retraction. Ear-
lier studies have reported loss of nitrergic neuronal cell bodies even
in the early phase of STZ-induced diabetes (16, 31, 34–36), though
not all studies examining at similar time points (8–16 weeks) after
STZ treatment found loss of myenteric neurons (8, 37). Despite
probable neuronal loss, the current study demonstrated intactness
of spatial arborization of nitrergic nerve terminals in the jejunum
after 16 weeks of diabetes induction. Our results are in coherence
with earlier observations of intactness of nNOS expression made
in stomach biopsies obtained from patient samples of diabetic
gastroparesis (38). Within the cell bodies, we have demonstrated
comparable levels of expression of nNOSα between untreated and
diabetes. The montage images of the cell bodies show the wide
variability of expression, reiterating that mere protein estimates
after blotting whole tissue extracts will provide inadequate insights
into the state of expression of nNOSα in untreated and diabetic
tissues. The results of the current study show that density of the
enteric nerve terminals serving unit area of muscularis externa is
comparable between diabetes and untreated, as also the intensity
of nNOSα within individual varicosities. Some diabetic tissues
have shown reduced expression of nNOSα both within the cell
bodies and the varicosities along the axons extending from these
cell bodies, but cumulatively, there were no significant alterations.
An earlier case report demonstrated loss of nitrergic innervation
in a human jejunum sample obtained from a patient with long
standing diabetes (39). These divergences in findings may have
primarily resulted from ongoing progressive pathophysiology of
nitrergic neurotransmission system.
The dissociation between unaltered expression of nNOSα and
grossly reduced expression of myosin Va within enteric neuro-
muscular nerve terminals is the most significant finding of this
study. This finding is highly significant, and provides a possible
basis of explanation why repeated observations have been made
of impaired pre-junctional NO synthesis, despite presence of NO
synthase within nerve terminals (1, 4, 10, 11). Because intravari-
cosity myosin Va deficiency has been demonstrated to be critical
for NO synthesis during neurotransmission (12, 14), it may be rea-
sonable to speculate that the findings of deficiency of myosin Va
within diabetic enteric nerve terminals may explain the impaired
pre-junctional NO synthesis seen in diabetes. It has been reported
that altered nNOS dimer/monomer ratio may be the basis of
impaired NO synthesis (9), and this may have resulted from defi-
ciency of tetrahydrobiopterin (40). Detailed biochemical analyses
have revealed that tetrahydrobiopterin may contribute to dimer
stabilization rather than dimer formation (41). It is possible that
myosin Va deficiency results in insufficient delivery of nNOSα
to the varicosity membrane, the likely function of myosin Va
within varicosities (12, 42). Future studies comparing membrane-
bound nNOSα dimer in wild type and diabetic tissues may resolve
these issues.
The present study probably is the first analyses examining
axonal transport of nNOSα and its force-generating cytoskeletal
allosteric partner myosinVa and provides valuable insights into the
mechanisms of axonal transport of soluble proteins. For myosin
Va in the untreated group, myosin Va was visualized as discrete
puncta along the nerve processes traversing the muscularis. A
continuous haze of staining was only visualized in some initial seg-
ments within the primary plexus. Being a soluble protein, myosin
Va likely undergoes slow transport, but may piggyback onto faster
transport systems as it progresses into the axon. Importantly, there
must be some mechanism for its capture at the axonal varicosities,
and this possibly contributes to the punctate appearance farther
along the axons. The intervaricose region here remains myosin
Va-stain free, indicating that myosin Va is possibly transported as
a macromolecular assembly along the axon. In diverse neuronal
systems, actin and NF-L have been reported to transport myosin
Va (28, 43). It remains to be examined, which allosteric protein
partner(s) contribute to axonal transport of myosin Va within
enteric neuronal processes. Interestingly, the axonal transport of
nNOSα is not affected or only minimally affected at the 16-week
time point examined in the present investigation. This may have
resulted from intact transport mechanism(s) of nNOSα during
the initial weeks of diabetes induction.
Most likely, nNOS-myosin Va do not form complex during
transport; otherwise, nNOSα stasis would also have occurred in
the neuronal cell bodies like that of myosin Va. This argument is
brought in because myosin Va and nNOS may be linked by the
common light chain LC8 (12, 44). However, it may be inferred
from the current observations that myosin Va and nNOS are inde-
pendently transported within the myenteric axons and tertiary
processes. Recent evidence and debates are revealing that soluble
proteins may not undergo the true form of slow axonal transport
as originally reported for soluble proteins with in vitro experi-
ments and radioactive pulse chase labeling (45–47). Such slow
rates of about 1 mm a day are practically impossible to deliver
proteins at the processes located several orders of distances away
(48–51). Incipient but convincing evidence have demonstrated
that soluble proteins tag on fast axonal transport systems and gets
rapidly transported to distal nerve terminals (52). The major fast
transport systems involve microtubules and kinesins (53). Specific
nNOS–kinesin interactions have not been reported, but kinesin
function deficit resulting from altered GDNF signaling in KIF26A
knockout has been reported to cause Hirschsprung-like pheno-
type with impaired nitrergic function (54). This important issue
merits future investigations. Though fast axonal transport is also
affected in diabetes, this usually results from long duration of
hyperglycemia. How nNOSα axonal transport is affected as a result
of prolonged duration of diabetes is a relevant avenue for future
testing. Incipient evidence is present regarding the existence of
periaxoplasmic ribosomal plaques, mRNA, and protein transla-
tion machinery in the axons, thus likely eliminating the bottleneck
necessity of synaptic and axonal protein transport (55–62). Such
evidence is virtually unknown for myenteric nitrergic neurons.
Though our report is novel from the perspective of being
the first report to demonstrate significant reduction of myosin
Va within varicosities in the peripheral nervous system, it has
been earlier reported that myosin Va is significantly reduced in
neuronal cell bodies in multiple brain regions several days after
STZ-induced diabetes (63). One intriguing question that posits
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from these observations is that if myosin Va is an important reg-
ulator of both vesicular and non-vesicular neurotransmission in
both the central and peripheral nervous system, how can neu-
ronal physiological function continue to operate, albeit at a lower
level of performance, despite reduction, or absence of myosin Va.
One likely reason of how neurotransmission function is sustained
in the face of diminished myosin Va may be due to neuroplas-
tic changes. For example, it has been reported that in the brain,
similar diabetic conditions that result in myosin Va reduction also
results in increased expression of non-muscle myosin II (NMMII)
(64). NMMII plays a critical role in vesicular neurotransmitter
release at the cortex of the nerve terminal. Whether NMMII plays
important role in nitrergic neurotransmission merits to be inves-
tigated, though increasing argument is being placed for critical
role of the cortical cytoskeleton in nitrergic neurotransmission
(14). Proteomic analyses in whole gut tissue and protein identi-
fication in varicosities have shown the presence of heavy chain
of NMMII (65), identified in the synaptosomes as Mg-dependent
ATPase (66). Myosin light chain kinase (MLCK), the enzyme that
activates NMMII, has been shown to be diminished in diabetes and
this dysregulation reversed by insulin (67). However, the localiza-
tion study was made in whole gut extracts and it is not known
whether MLCK was down regulated in nerve terminals or smooth
muscles or both.
Myosin Va expression in myenteric ganglia is much reduced
in diabetic tissues in comparison to nNOSα and it seems likely
that this selective reduction has taken place early on after diabetes
induction. Earlier studies have actually shown increased nNOS
mRNA in male diabetic tissues (9). It is possible that the transcrip-
tion factor or factors that drive myosin Va genomic synthesis are
exquisitely sensitive to the pathophysiological alterations resulting
from STZ-induced diabetes. For example, down regulation of the
snail transcription factor that binds to an E-box in the promoter
region of myosin Va gene (68) may have inhibited myosin Va syn-
thesis. It is increasingly recognized that persistent hyperglycemia
can alter transcription because basal transcription operators and
repressors are sensitive to intracellular glucose concentrations
(36, 69, 70).
Independent reports have confirmed increased VIP-IR of nerve
varicosities several weeks after STZ-induced diabetes (7, 71, 72),
though studies in human diabetic tissues have not always con-
firmed these findings (38). While this may be related to neuro-
plastic changes resulting from decrease in nitrergic synthesis, the
increased VIP-IR may also be related to diminution of vesicular
exocytosis at the junctions (73), probably resulting from deficiency
of the motor protein myosin Va. ATP exocytosis has been reported
to be enhanced in diabetic enteric nerve terminals (74). This appar-
ently confounding finding may be possible due to compensatory
changes in purinergic signaling resulting from diminution in pre-
junctional NO synthesis. Our observations of increased perikaryal
volumes of some myosin Va neurons in diabetes may have resulted
from attenuation of axonal transport. The relationship of stasis as
a fundamental pathophysiology of diabetic neuropathy has long
been recognized (75, 76).
Controlling hyperglycemia in the periphery through ethnophar-
macologic glucosidase inhibitor obtained from Pouteria has the
potential to reverse the loss of myosin Va in central nervous system
neurons (77). This is similar to previous observations of reversal
of nitrergic neuropathy by insulin treatment (8, 32). Thus, there
is a potential for pharmacological reversal of myosin Va transcrip-
tional inhibition, at least in the early phases after STZ induction
of diabetes.
In summary, the results of the present study show the disso-
ciation between presences of the key inhibitory neurotransmitter
synthesizing enzyme nNOSα in the nerve terminals but absence of
its local transporter myosin Va in the jejunum of rats after 16 weeks
of diabetes induction with STZ. Earlier studies with dilute mice
have shown that nNOSα may be present in the nerve varicosities
despite deficient myosin Va (12). Surprisingly, similar observa-
tions were made in diabetic nerve terminals in the present study.
STZ is uptaken by cells with the aid of GLUT2 transporter (78).
STZ causes promoter methylation, gene inactivation, and cellu-
lar toxicity (78). It may be possible that alterations of myosin Va
expression may have resulted from STZ toxicity of myenteric gan-
glia. However, this possibility is low because we did not observe
global inhibition of transcription or generalized cell loss. Low dose
STZ was used for the current study in accordance with previous
studies, which was used as model for diabetes induction (79–82).
The validity of our observations may be confirmed from differ-
ent models of diabetes including genetic and lipotoxic models,
examining different regions of the gastrointestinal tract and the
temporal progression of disease. This significant observation of
deficient myosin Va in nerve terminals may potentially explain
impairment of pre-junctional NO synthesis during EFS of dia-
betic gut neuromuscular strips despite presence of the nitrergic
synthetic enzyme nNOS.
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